Monthly shot aims to slow MS progression
NCT ID NCT03362294
First seen Apr 23, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This study tested a long-acting form of glatiramer acetate (GA Depot) given as a monthly shot to people with primary progressive multiple sclerosis (PPMS). The goal was to see if it could safely slow down worsening disability. The study planned to enroll 30 adults aged 18-65 with PPMS, but it was terminated early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mapi Pharma Research site 01
Tel Aviv, Israel
-
Mapi Pharma Research site 06
Rehovot, Israel
-
Mapi Pharma Research site 07
Jerusalem, Israel
-
Mapi Pharma Research site 08
Petah Tikva, Israel
-
Mapi Pharma Research site 09
Haifa, Israel
-
Mapi Pharma Research site 20
Chisinau, Moldova
-
Mapi Pharma Research site 22
Chisinau, Moldova
Conditions
Explore the condition pages connected to this study.